Literature DB >> 22754891

Consider adding this drug to fight COPD that's severe.

Keia Hobbs, Dionna Brown.   

Abstract

Daily use of azithromycin, in conjunction with the usual COPD regimen, has been found to reduce acute exacerbations in patients with moderate to severe disease.

Entities:  

Year:  2012        PMID： 22754891      PMCID： PMC4280070     

Source DB:  PubMed          Journal:  J Fam Pract        ISSN： 0094-3509            Impact factor:   0.493


  8 in total

Review 1.  Macrolide antibiotics for cystic fibrosis.

Authors:  Kevin W Southern; Pierre M Barker; Arturo Solis-Moya; Latifa Patel
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

2.  Acute exacerbations of COPD in the United States: inpatient burden and predictors of costs and mortality.

Authors:  Prasadini N Perera; Edward P Armstrong; Duane L Sherrill; Grant H Skrepnek
Journal:  COPD       Date:  2012-03-12       Impact factor: 2.409

3.  Inhibitory effects of macrolide antibiotics on exacerbations and hospitalization in chronic obstructive pulmonary disease in Japan: a retrospective multicenter analysis.

Authors:  Mutsuo Yamaya; Arata Azuma; Hiroshi Tanaka; Hajime Takizawa; Kingo Chida; Yoshio Taguchi; Keiichi Mikasa; Junichi Kadota; Shoji Kudoh
Journal:  J Am Geriatr Soc       Date:  2008-07       Impact factor: 5.562

4.  Azithromycin for prevention of exacerbations of COPD.

Authors:  Richard K Albert; John Connett; William C Bailey; Richard Casaburi; J Allen D Cooper; Gerard J Criner; Jeffrey L Curtis; Mark T Dransfield; Meilan K Han; Stephen C Lazarus; Barry Make; Nathaniel Marchetti; Fernando J Martinez; Nancy E Madinger; Charlene McEvoy; Dennis E Niewoehner; Janos Porsasz; Connie S Price; John Reilly; Paul D Scanlon; Frank C Sciurba; Steven M Scharf; George R Washko; Prescott G Woodruff; Nicholas R Anthonisen
Journal:  N Engl J Med       Date:  2011-08-25       Impact factor: 91.245

Review 5.  Prophylactic antibiotic therapy for chronic bronchitis.

Authors:  T Staykova; P N Black; E E Chacko; P Poole
Journal:  Cochrane Database Syst Rev       Date:  2003

6.  Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study.

Authors:  Christine R Jenkins; Paul W Jones; Peter M A Calverley; Bartolome Celli; Julie A Anderson; Gary T Ferguson; Julie C Yates; Lisa R Willits; Jörgen Vestbo
Journal:  Respir Res       Date:  2009-06-30

7.  Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.

Authors:  Marc Decramer; Bartolome Celli; Steven Kesten; Theodore Lystig; Sunil Mehra; Donald P Tashkin
Journal:  Lancet       Date:  2009-08-27       Impact factor: 79.321

8.  Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations.

Authors:  Terence A R Seemungal; Tom M A Wilkinson; John R Hurst; Wayomi R Perera; Ray J Sapsford; Jadwiga A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2008-08-21       Impact factor: 21.405
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.